A Phase I Safety Study of CRB-4001 for the Treatment of Nonalcoholic Steatohepatitis (NASH)/ Nonalcoholic fatty liver disease (NAFLD)

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 12 Feb 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CRB-4001 (Primary)
Indications Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
Focus Adverse reactions; First in man
Sponsors Corbus Pharmaceuticals

07 Feb 2020 According to an Corbus Pharmaceuticals media release, the company announced the pricing of an underwritten public offering of 6,666,667 shares of its common stock. The company intends to use the net proceeds of the proposed underwritten offering to fund its continued development of CRB-4001 for clinical trials.
11 Nov 2019 According to an Corbus Therapeutics media release, data from this study is expected in 2020.
07 Nov 2019 According to an Corbus Therapeutics media release, this trial is expected to start in 2020.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com